Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma

NCT03219775 is registered in ClinicalTrials.gov with AIO-Studien-gGmbH as lead sponsor.

NCT NCT03219775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03219775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma
Lead sponsor
AIO-Studien-gGmbH
Phase
Phase 2
Overall status
Unknown status
Start date
July 6, 2017
Completion date
February 18, 2023
Enrollment
169 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, metastatic cancer, transitional cell carcinoma